KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Share-based Compensation (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Share-based Compensation data on record, last reported at $5.3 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 23.26% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $16.2 million, down 10.0%, while the annual FY2025 figure was $16.2 million, 10.0% down from the prior year.
  • Share-based Compensation reached $5.3 million in Q4 2025 per EBS's latest filing, up from $4.8 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $12.3 million in Q2 2022 and bottomed at $1.5 million in Q1 2025.
  • Average Share-based Compensation over 5 years is $7.2 million, with a median of $6.4 million recorded in 2023.
  • The widest YoY moves for Share-based Compensation: up 108.7% in 2025, down 74.58% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $10.1 million in 2021, then grew by 15.84% to $11.7 million in 2022, then plummeted by 65.81% to $4.0 million in 2023, then increased by 7.5% to $4.3 million in 2024, then grew by 23.26% to $5.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $5.3 million in Q4 2025, $4.8 million in Q3 2025, and $4.6 million in Q2 2025.